Data Characteristics for this Category
siRNA nucleic acid drug data originates from clinical trial reports, patent literature, research papers, regulatory databases (e.g., FDA Orange Book, EMA HMA), and internal experimental data. Data update frequencies vary. Clinical trial data is released in stages as trials progress, while patents and papers follow publication cycles. Document structures typically include target information, sequence design, modification strategies, in vitro and in vivo efficacy, toxicology data, pharmacokinetic parameters (e.g., half-life, volume of distribution), and formulation process descriptions. Key fields include specific sequences (sense/antisense strand), chemical modification sites, target gene expression inhibition rates, IC50/EC50, and plasma concentration-time curve parameters (AUC, Cmax). Units cover molar concentration (nM), inhibition percentage (%), time (h), and dose (mg/kg).
Constraints on "Forms and Interaction"
The diverse sources and complexity of siRNA nucleic acid drug data impose high demands on form design. Sequence information requires precise text input and structured validation, such as limiting nucleotide types and modification symbols. Efficacy and toxicology data often appear in tables or graphs, requiring forms to parse and link these data points. Clinical trial reports are lengthy and have varied formats. This requires enhanced parsing capabilities for extracting key fields directly from documents, and may necessitate user confirmation or correction of identified results. Inconsistent update frequencies mean that data timestamps and sources must be clearly indicated in data entry and query interfaces to prevent the misuse of outdated information. Furthermore, standardized units and automatic conversion features for fields involving chemical structures and biological effects are crucial to prevent user input errors.
Configuration Settings
| Configuration Item | Suggested Value | Rationale |
|---|---|---|
maxContext | 4000 token | Accommodates long clinical reports while maintaining processing efficiency. |
Chunk size (Segment Length) | 800 characters | Ensures sufficient semantic content per segment without excessive length. |
Similarity threshold (Similarity Threshold) | 0.78 | Achieves precise matching for critical information like sequences and targets. |
Rerank result count (Rerank Return Count) | Top 5 entries | Filters for the most relevant results, reducing user effort. |
PARSE_FILE_TIMEOUT_SECONDS | 300 seconds | Handles parsing times for large PDFs or multi-page Excel reports. |
Allowed File Types | pdf, docx, xlsx, txt | Covers common scientific research and clinical document formats. |
Common Pitfalls
- Symptom: The system prompts "Incorrect input format" after a user submits a sequence, but the user confirms the sequence is correct. Reason: The form does not clearly prompt for, or support, specific nucleotide modification symbol input standards.
- Symptom: Querying efficacy data for a specific siRNA product returns empty or incomplete results. Reason: Document parsing failed to accurately identify IC50/EC50 values in tables or incorrectly associated dose units.
- Symptom: Executing a "code execution" step in a workflow fails validation when "history" is included as input. Reason: The structure or fields of the history record do not match the expected input parameters for code execution; proper format conversion or extraction was not performed.
Verification Steps
- Submit an siRNA sequence containing typical nucleotide modifications. Check if the form correctly receives and stores it, and verify the backend validation logic.
- Upload a PDF or Excel file containing efficacy data (e.g., IC50/EC50 tables). Verify that the data is correctly parsed and populated into the corresponding fields.
- In a simulated query scenario, input a specific target or gene name. Check if the returned results include detailed information about relevant siRNA products, and verify that their update times align with the original data sources.
The values provided are common starting points. Measure against your own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.